DPS Appoints Aidan O’Dwyer President of U.S. Project Operations, Life Sciences Division

Aidan O’Dwyer

BOSTON – DPS, a global architecture and engineering firm serving the life sciences industry, announced the appointment of Aidan O’Dwyer as President of U.S. Project Operations, Life Sciences division, and as a member of the DPS Board of Directors effective immediately.

As president, O’Dwyer is charged with providing strategic leadership to guide DPS expansion in the U.S. through development and acquisition. He brings more than 22 years of biotech and pharmaceutical industry experience to his new role having previously served as the Senior Vice President of Operations for DPS in Framingham, Mass., since 2011, when the firm opened its first U.S. life sciences division through the acquisition of BioMetics. O’Dwyer played a pivotal role in expanding the operation’s portfolio and growing the team from eleven employees to currently a staff of over 130.

Aidan O’Dwyer

“Recognizing our success in the U.S. over the past six years under Aidan’s leadership, and in view of our future expansion plans and investment, it was critical to put a structure in place to continue to advance our firm’s strategic initiatives,” said Frank Keogh, CEO, DPS. “We are confident in Aidan’s proven leadership ability coupled with his keen business sense and industry insight to lead U.S. project operations and to competitively position DPS in other strategic locations to drive our sustainable growth.”

DPS’ U.S. Life Sciences offers full architecture and engineering services, commissioning, qualification and validation, and construction management services for companies including Sanofi Genzyme, AbbVie, Shire, Pfizer, Eli Lilly, Avecia Nitto Denko, Moderna Therapeutics, Biogen and Seres Therapeutics – to name a few.

Prior to his current role as president and SVP, O’Dwyer held senior management positions with the firm starting as a construction manager in 2005, and later as a senior project manager responsible for the delivery of capital projects ranging in value from $10 – $100M for clients such as Pfizer, Merck, GSK, Eli Lilly and Janssen, across various geographic locations, which included Ireland, the United Kingdom, Holland and Belgium. Before joining DPS, O’Dwyer held senior project management positions with a number of global blue-chip pharmaceutical firms, where he played key roles in the delivery of capital programs ranging from $150 – $350M.

“I’m excited and honored to take on this new position, and look forward to partnering with our senior leadership as we continue to deliver on our strategic vision and fostering long-term relationships with our life sciences clients throughout the U.S.,” said O’Dwyer.